Tscan Therapeutics Inc (TCRX NASDAQ) stock market data APIs
$1.2211
0.03(2.5%)
as of May 5, 2026
Try our APIs with
free plan!
Tscan Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Prev. Close
1.2211
Open
1.2531
High
1.2594
Low
1.1874
52 wk Range
0.8824-2.57
Market Cap
72 723 K
Shares Outstanding
55 825 K
Revenue
10 325 K
EPS
-0.18
Beta
1.063
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Tscan Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tscan Therapeutics Inc data using free add-ons & libraries
Get Tscan Therapeutics Inc Fundamental Data
Tscan Therapeutics Inc Fundamental data includes:
- Net Revenue: 10 325 K
- EBITDA: -130 947 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-11
- EPS/Forecast: -0.2671
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tscan Therapeutics Inc News
New
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T ce...
Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space
TScan Therapeutics, Inc. (NASDAQ:TCRX) is among the top 10 stocks under $5 that could triple.Strong Analyst Sentiment on TScan Therapeutics (NASDAQ) Amid Ongoing Momentum in Cell Therapy Space A dose...
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.53 per share a year ago. These ...
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $1.97. This compares to a loss of $1.74 per share a year ago. These figu...
Get Tscan Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
